Sanofi Ventures — Full Portfolio
97 tracked investments · listed companies and verified rows first
Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)Bahram (Bob) Valamehr(President & Chief Executive Officer)
BoardAmir Nashat(Director)inJohn Mendlein(Director)
Co-investorsVenrockPolaris Partners
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+3 more
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Co-investorsHavencrest Capital ManagementRidgeback CapitalRiverVest Venture Partners
Omada Health provides virtual-first, integrated care programs for chronic disease management, delivered as data-driven solutions for employers, health plans, and healthcare organizations.
Digital HealthHealthtechWellness & FitnessSan Francisco, US
Andrew DiMichelle(Executive Officer, Director)Adrian James(Executive Officer, Director)inSean Duffy(Executive Officer, Director)inWei-Li Shaoin
BoardJonathan Root(Director)inCasper De Clercq(Director)in
Co-investorsAndreessen HorowitzBlackbird GiantsCanvas VenturesCivilization Ventures Management, LlcDesigner FundFounder Collective+12 more
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)David Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedCU Healthcare Innovation FundOUP (Osage University Partners)Agent Capital
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatJason P. Hafler· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalMass General Brigham VenturesREDMILE+8 more
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSofinnova PartnersVIVES PartnersApollo Health VenturesSixty Degree Capital
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsAccess BiotechnologyCanaan PartnersSV Health InvestorsSR One Capital ManagementBritish Business BankJanus Henderson Investors
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)in
Co-investorsNovartis Venture FundForbionVersant Ventures
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Co-investorsARCH Venture PartnersAtlas Venture5AM Ventures
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedPureos BioventuresSunstone CapitalEQT Life Sciences+2 more
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more
OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.
BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB
Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)Jonathan Hopper(Vice President, Platforms and Founder)Hsin Yung (Jason) Yen(Founder)inRos Deeganin
Co-investorsGV (Google Ventures)Oxford Science EnterprisesNorthpond Ventures
QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.
AI & Machine LearningBiotechDeep Tech
Co-investorsOrbiMedCreacion VenturesLilly Asia Ventures
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsNovartis Venture FundRoche Venture FundYsios CapitalAsabys PartnersCriteria Bio VenturesNew Enterprise Associates (NEA)+2 more
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)Laia Crespo-Martin(Director)
Co-investorsMRL Ventures FundSV Health InvestorsAngelini VenturesMitsui Global InvestmentApollo Health VenturesDementia Discovery Fund+1 more
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatChristopher Gagliardi· per SEC Form D
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAbingworth+2 more
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.
BiotechDigital HealthHealthtechMedical DevicesNew York, US
David B. Klein(Founder and CEO)inDavid Klein(Executive Officer, Director)inRandall Stanicky(Executive Officer)in
BoardAlex Zisson(Director)Lee Shapiro(Director)in
Board seatCris De Luca· per SEC Form D
Co-investorsAccelmed PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersHealth Catalyst CapitalHikma VenturesSupernode Ventures+2 more
BiotechDel Mar, US
Matthew Disney(Director)Paul Stone(Executive Officer)inYujiro Hata(Director)Kevin Forrest(Executive Officer, Director)
BoardScott Rocklage(Executive Officer, Director)inJason Hafler(Director)in
Board seatJason P. Hafler· per SEC Form D
Co-investors5AM VenturesKleiner PerkinsNovartis Venture Fund
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Cambridge, US
Board seatJason P. Hafler· per SEC Form D
Co-investorsAccess BiotechnologyDigitalis Ventures
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)Michelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)Gary Patou(Executive Officer)
Board seatJason P. Hafler· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSofinnova VenturesAgent CapitalBlue Owl Capital+8 more
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Board seatJason P. Hafler· per SEC Form D
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)The Column GroupAbingworth+3 more
AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US
Anar Isman(Co-Founder & Chief Executive Officer)Robert Michael Pejovich(Director of Finance of the Issuer)
Co-investors1/1 Capitalabrdn plcAngelini VenturesFidelity InvestmentsJanus Henderson Investors
Co-investors+ND CapitalSolasta Ventures
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundRiverVest Venture Partnersabrdn plcEQT Life Sciences
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)in
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestVida VenturesGoldman Sachs
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)STEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCMedical Excellence CapitalRA CapitalOpenSky Ventures
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsARCH Venture PartnersRA Capital
Branchlab offers an AI-driven platform for healthcare marketing that helps teams explore patient, HCP, and caregiver audiences without exposing Protected Health Information, then create, optimize, and activate those audiences across channels.
AI & Machine LearningHealthtechMarketing TechNew York, US
Joshua Walsh(Executive Officer, Director)Christopher Cagle(Executive Officer, Director)
BoardMichael Parkes(Director)inCarrie Williams(Director)inAndrew Bouldin(Director)in
Co-investorsAIX VenturesFCA Venture PartnersMcKesson VenturesNext VenturesNVP CapitalSwift Ventures+2 more
Carbon Health operates a chain of clinics offering urgent care, primary care, and chronic condition management, combining technology with in-person care to provide broader access to health services.
Digital HealthHealthtechMedia & Entertainment
Eren Bali(Founder)Greg BurrellinTom Berry
Co-investors500 Emerging Europe500 GlobalAkkadian VenturesAnnex InvestmentsBuilders VCDCVC (Data Collective)+13 more
Character Bio is a precision medicine company that integrates genomics, longitudinal clinical data, imaging, and AI-based biomarker analysis to identify genetic drivers of progressive polygenic eye diseases such as age-related macular degeneration and glaucoma.
AI & Machine LearningBiotechDigital HealthJersey City, US
Cheng Zhang(Executive Officer, Director)in
BoardVivek Garipalli(Director)Nick Olsen(Director)Peter DiLaura(Director)
Co-investorsaMoonCantos VenturesCatalio Capital Management, LPDuke Capital PartnersLifeforce CapitalCatalio Capital Management+3 more
HealthtechCambridge, US
Richard Whalley(Executive Officer, Director)James White(Executive Officer, Director)
BoardPatrick Flynn(Director)
Co-investorsQualcomm VenturesWaterline Ventures
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)
Co-investorsAdjuvant CapitalOrbiMedRA CapitalHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Manhattan Beach, US
Peter Kim(Executive Officer, Director, Promoter)Francis Lam(Executive Officer, Director, Promoter)
BoardBill Geary(Director)inMohamad Makhzoumi(Director)in
Co-investorsFlare Capital PartnersGreen Bay VenturesNew Enterprise Associates (NEA)Shuttle Fund
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Co-investorsAtlas VentureEcoR1 CapitalFrazier Life Sciences
London, US
Sarim Siddiqui(Executive Officer, Director)Maroof Ahmed(Executive Officer, Director)Yusuf Sherwani(Executive Officer, Director)
Co-investorsManta Ray VenturesAccelmed PartnersAtomicoH.I.G. BioHealth Partners
Eligo Bio works on the role of bacterial genes in triggering or worsening disease, applying genetic causality across a range of therapeutic areas.
BiotechDeep TechHealthtech
Co-investorsNSG VenturesVIVES Partners
Empatica offers an FDA-cleared health monitoring platform combining medical wearables and digital biomarkers to collect continuous, clinical-quality health data from daily life.
AI & Machine LearningDigital HealthHealthtechMedical DevicesCambridge, US
Rosalind Picard(Founder and Director of the Affective Computing Group at the MIT Media Lab and Faculty Chair, MIT Mind+Hand+Heart Wellbeing Initiative)inMatteo Lai(Executive Officer, Director)inSimone Tognetti(Director)inLen Picard(Executive Officer, Director)inMario Scuderi(Director)
Co-investorsBlack Opal VenturesCDP Venture CapitalRA Capital
Company measuring health in everyday life via a permissioned real-world data platform.
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.
BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US
Christine Lemke(Executive Officer, Director)inDeborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein
BoardDavid Fleshman(Director)Rowan Chapman(Director)
Co-investorsAsset Management CompanyB Capital GroupB4 CapitalCross Creek AdvisorsFresco CapitalG Squared+4 more
Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.
BiotechHealthtechMedical DevicesSan Francisco, US
Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)
Co-investorsForbionNovo HoldingsSofinnova Ventures
GlycoMimetics is a company developing cancer therapies, aiming to advance treatment options for people living with cancer.
BiotechHealthtech
Co-investorsNew Enterprise Associates (NEA)
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)
BoardPeter C.M. McWilliams(Director)Giacomo Chiesi(Director)Christopher Starr(Director)
Co-investorsAdvent Life SciencesChiesi VenturesCTI Life Sciences Fund L.P.Remiges Ventures, Inc.RiverVest Venture PartnersSanderling Ventures
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.RiverVest Venture PartnersSanderling Ventures
Data & InfrastructureDigital HealthHealthtechNew York, US
Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)
Co-investorsB Capital GroupB4 CapitalBlue Lion GlobalFlare Capital PartnersForesite CapitalLG Technology Ventures+6 more
A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.
Biotech
Co-investors7G BioVenturesCerity Partners VenturesHikma Ventures
Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investors7G BioVenturesJDRF T1D Fund
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
BoardPeter Kolchinsky(Director)in
Co-investorsRA CapitalQiming Healthcare
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)Albert M. Kim(Chief Medical Officer)
Co-investorsAN Venture PartnersRA CapitalSV Health InvestorsCatalio Capital Management
BiotechSeattle, US
Carlos V. Paya(Executive Officer, Director)Ed Penhoet(Director)Stephen R. Brady(Executive Officer)Jan Henrik ter Meulen(Executive Officer)David Baltimore(Director)William Ringo(Director)
Co-investorsOUP (Osage University Partners)
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)Martin Edwards(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Sofinnova VenturesPivotal Life Sciences
The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.
Gaming
Co-investors5AM Ventures
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.
BiotechDeep TechHealthtechWaltham, US
Mark Vignola(Chief Financial Officer)inJonathan Violin(President)
Co-investorsTCG CrossoverVenrockWellington Management
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLC5AM VenturesWestlake Village BioPartners
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdangHans van der Vliet(Head of Innovation)Steve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)
Co-investorsMRL Ventures FundYsios Capital
Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.
AI & Machine LearningBiotechDeep Tech
Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)
Co-investorsAtlas VentureDigitalis Ventures
Medisafe is a medication engagement platform that helps pharmaceutical companies connect with patients beyond the prescription and improve treatment adherence.
Digital HealthHealthtechMedical DevicesBoston, US
Rotem Shor(Founder)
Co-investors7wire VenturesALIVE Israel HealthTech FundCorewell Health VenturesLool VenturesM VenturesQualcomm Ventures+2 more
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)
BoardZach Scheiner(Director)inMegan Krench(Director)Dmitrij Hristodorov(Director)in
Co-investorsAvego BioScience CapitalForbionRA CapitalSamsara BioCapital
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)
BoardPaul Berns(Director)
Co-investorsARCH Venture PartnersOrbiMed
Muna Therapeutics is a biotechnology company that discovers and develops therapies aimed at slowing or stopping neurodegenerative diseases, including Alzheimer's and Parkinson's.
BiotechLongevity
Rita Balice-Gordon(Founder)in
Co-investorsDroia VenturesSofinnova PartnersV-Bio Ventures
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)Brian Gallagher(Director)in
Co-investorsage1Brace PharmaAtlas VenturePolaris PartnersSR One Capital Management
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactCatalio Capital ManagementInvusLeaps by BayerSixty Degree Capital
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)Chris Guiffre(Executive Team)Alan P. Watt(Executive Team)Jyothis George(Chief Medical Officer)Nick Clarke(Executive Team)
Co-investors5AM VenturesEpidarex CapitalF-Prime CapitalSofinnova Partners
Co-investorsM VenturesSAV (Scale Asia Ventures)
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsThe Column GroupSamsara BioCapital
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.
BiotechHealthtechMedical Devices
Pamela Conley(Founder)in
Co-investorsB Capital GroupB4 CapitalGlobal BioAccess FundMission BiocapitalDigitalis VenturesNorwest Venture Partners
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+6 more
Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments.
BiotechHealthtechMedical DevicesNew York, US
Jeremy M. Levin(Co-founder and Executive Chairman)Meg Alexander(President & Chief Executive Officer)inCharles Carter(Chief Financial Officer)Victoria Fort(Chief Strategy Officer)inPetra Kaufmann(Chief Medical Officer)Manal Morsy(Chief Regulatory Officer)
Co-investorsBioBrit
Co-investorsAvoro Capital Advisors
QuantHealth provides clinical trial design optimization tools that help pharmaceutical and biotech companies evaluate trial outcomes, competitive positioning, and enrollment feasibility to reduce development risk and accelerate timelines.
AI & Machine LearningBiotechDigital HealthHealthtech
Orr Inbar(Chief Executive Officer)inArnon Horevin
Co-investorsIsrael Innovation AuthorityATOORO FUNDNina CapitalNovaCapitalShoni Health Ventures
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSV Health InvestorsAmgen Ventures+6 more
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)
Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine.
BiotechDigital HealthHealthtechMedical Devices
Tyler Van Horn(Chief Executive Officer)inDebra Weinstein(Chief Medical Officer)in
Co-investorsGlynn Capital ManagementLux CapitalInertia Ventures
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)
Co-investorsFrazier Life SciencesMonograph Capital PartnersSV Health InvestorsDementia Discovery FundTPG
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB
Co-investorsF-Prime CapitalSofinnova PartnersCambridge Innovation CapitalDigitalis Ventures
Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines, with a focus on immunology and the immune system.
AI & Machine LearningBiotechHealthtech
Co-investorsMRL Ventures FundNew Enterprise Associates (NEA)Rho VenturesFJ Labs
Trial Library operates an AI-native platform that integrates clinical trials into routine care, activating providers, identifying eligible patients, and guiding them through the trial lifecycle.
AI & Machine LearningDigital HealthHealthtech
Co-investorsHow Women InvestLux CapitalNext VenturesOverwater Ventures LlcSeae VenturesSemperVirens Venture Capital+1 more
Ultragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases.
BiotechHealthtechMedical Devices
Co-investorsF-Prime Capital
Co-investorsHatteras Venture Partners
Voluntis provides a regulated digital health platform for pharmaceutical and medtech companies to build and manage patient-facing solutions across the patient journey, including symptom management, adherence and dosage support.
Digital HealthHealthtechSaaS
Co-investorsEisai Innovation, Inc.KaristaVesalius Biocapital Partners
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSR One Capital ManagementJanus Henderson InvestorsNovo Holdings+3 more
Co-investorsAltium CapitalDolby Family Ventures
Zag Bio develops bifunctional antibodies that target the thymus to deliver self-antigens to antigen-presenting cells, training regulatory T cells to restore immune tolerance.
BiotechHealthtech
Co-investorsLightspeed Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.